Nurix Therapeutics (NRIX) CSO Gwenn Hansen Sells Shares

What Happened

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), sold a total of 4,111 shares on August 4, 2026 in two open-market transactions. The sales were: 1,500 shares at a weighted average price of $23.87 ($35,803) and 2,611 shares at a weighted average price of $24.64 ($64,339), for total proceeds of about $100,142. These were disposals (sales), which are generally routine and do not necessarily signal management sentiment.

Key Details

• Transaction dates and prices:
  • 2026-08-04: 1,500 shares sold @ weighted avg $23.87 (total $35,803). Price range reported: $23.42–$24.38. (Footnote)
  • 2026-08-04: 2,611 shares sold @ weighted avg $24.64 (total $64,339). Price range reported: $24.43–$24.83. (Footnote)
• Aggregate shares sold: 4,111; aggregate proceeds: ≈ $100,142.
• Footnotes: At least one sale was effected pursuant to a Rule 10b5-1 trading plan (per filing). The filing reports weighted-average prices and gives ranges; detailed per-price breakdowns are available upon request to the SEC staff or issuer.
• Shares owned after the transactions: not specified in the provided excerpt.
• Filing timeliness: Report filed on 2026-08-05 for transactions on 2026-08-04 (filed promptly).

Context

• Sales executed under a Rule 10b5-1 plan are pre-arranged and can be routine, helping insiders avoid timing accusations; they do not necessarily reflect a change in the insider’s view of the company.
• For retail investors, purchases by insiders typically carry more informational weight than routine sales; this report documents routine disposals rather than a new acquisition.